Amarillo Biosciences Inc.
Amarillo Biosciences Inc.: Amarillo Biosciences Appoints Dr. Peter Mueller Chief Operating Officer and
Amarillo Biosciences Inc. / Change of Personnel Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Amarillo Biosciences Appoints Dr. Peter Mueller Chief Operating Officer and Director of Research Amarillo, Texas, April 14, 2008 — Amarillo Biosciences, Inc. (OTCBB: AMAR), a specialty pharmaceutical company focused on low‐dose orally administered interferon as a treatment for a variety of conditions, today announced that Peter Mueller, Ph.D. has been appointed Chief Operating Officer and Director of Research. Dr. Mueller will be responsible for research and development, business development, licensing, global commercial development, production and administration at the company. He will be actively involved in the development of strategic alliances and business opportunities with other companies and organizations. Dr. Mueller has more than 20 years of global experience in the pharmaceutical industry. Most recently, he has headed Epicenter Consulting Inc., a New Jersey based health care consulting firm that he founded in 2001. Previously, Dr. Mueller was Vice President, Global Marketing & Medical Information and Technology for Aventis Pharmaceuticals. Prior to that position, he served as Vice President, Global Marketing Business & Marketing Services for Hoechst Marion Roussel. He was also Director, Global Commercial Development, Cardiovascular and Metabolism for Marion Merrell Dow. Dr. Mueller is a pharmacist with a Ph.D. degree in pharmaceuticals from the University of Mainz, Germany. 'Peter is a dynamic and results‐driven executive with extensive global experience in the pharmaceutical industry,' observed Dr. Joseph Cummins, President and Chief Executive Officer of Amarillo Biosciences. 'His strong organizational skills coupled with his dedication to the achievement of strategic and tactical objectives, will greatly aid our company’s efforts to achieve FDA approval for the utilization of our low‐dose interferon in the treatment of multiple medical conditions.' Dr. Cummins added, 'Dr. Mueller’s proven track record for achieving organizational as well as market‐based objectives will be invaluable to Amarillo Biosciences. As a consultant, Dr. Mueller completed major projects for large pharmaceutical and biotech companies in the United States and Europe, and we are highly confident that his management skills and network of business associates will accelerate the company’s development of its low‐dose interferon technology platform. I am particularly delighted that Dr. Mueller’s energy and contributions will allow me more time to fully study new clinical applications for oral interferon and file new patent applications.' 'Prior to joining Amarillo Biosciences, I conducted a great deal of research and due diligence on the company’s technology and prospects to target both large and orphan market opportunities, and I am confident that the company can rapidly develop into a significant specialty pharmaceutical company,' said Dr. Mueller. Dr. Mueller further commented, 'Amarillo Biosciences is on the cusp of proving the efficacy and benefits of its low‐dose oral interferon technology. The key to its global success will involve the development of oral Interferon for the treatment of chronic cough in chronic obstructive pulmonary disease (COPD) – which is estimated to affect more than 600 million people worldwide—and for thetreatment of influenza and hepatitis C, which also have large global market potential.' About Amarillo Biosciences, Inc. Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which owns 10.5% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments to the company. Amarillo Biosciences’ primary focus involves extensive and ongoing R&D into the utilization of low‐dose, orally administered interferon as a treatment for a variety of conditions, including chronic cough (COPD), influenza, and opportunistic infections in patients who are HIV positive. In its 23‐year history, the Company has invested nearly $39 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for low‐dose oral interferon. Additional information is available on the web site at http://www.amarbio.com/. Except for the historical information contained herein, the matters discussed in this news release are forward‐looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other governmentapprovals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see 'Item 1. Description of Business' of the Company’s Form 10‐KSB for the year ended December 31, 2007. Investor Relations: Philippe Niemetz PAN Consultants, Ltd. e-mail:p.niemetz@panconsultants.com Tel: 800-477-7570; 212-344-6464 Fax: 212-618-1276 Joseph M. Cummins, DVM, PhD Amarillo Biosciences, Inc. e-mail:jcummins@amarbio.com Tel: 806-376-1741 x 13 Fax: 806-376-9301 14.04.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden